StockData
Iovance Biotherapeutics, Inc. logo

Iovance Biotherapeutics, Inc. (IOVA) stock

IOVANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3087% above fair value
$7.53−0.02 (-0.26%)

Close on Nov 17, 2026Market cap $3.41BP/E –Yield –

Iovance Biotherapeutics operating margin

Operating margin is operating income as a percentage of revenue.

Iovance Biotherapeutics's operating margin for the twelve months ending Jun 30, 2026 was -92.7%. For fiscal 2025 it was -153.1%, against -240.9% the year before.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-153.1%+87.8
FY2024Dec 31, 2024-240.9%+38494.1
FY2023Dec 31, 2023-38735.0%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-52.3%+137.5
Q1 FY2026Mar 31, 2026-113.5%+132.3
Q4 FY2025Dec 31, 2025-84.7%+32.8
Q3 FY2025Sep 30, 2025-140.7%+11.4
Q2 FY2025Jun 30, 2025-189.8%+137.9
Q1 FY2025Mar 31, 2025-245.8%+16218.9
Q4 FY2024Dec 31, 2024-117.5%+25039.4
Q3 FY2024Sep 30, 2024-152.1%+25084.8
Q2 FY2024Jun 30, 2024-327.6%+45927.0
Q1 FY2024Mar 31, 2024-16464.6%–
Q4 FY2023Dec 31, 2023-25156.8%–
Q3 FY2023Sep 30, 2023-25236.9%–
Q2 FY2023Jun 30, 2023-46254.6%–

More Iovance Biotherapeutics figures

See a number that looks wrong?